Navigation Links
King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Date:8/30/2007

CRANBURY, N.J. and BRISTOL, Tenn., Aug. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today that they have delayed plans for the initiation of Phase 3 clinical trials with bremelanotide, a first in class melanocortin agonist drug candidate, for the treatment of male erectile dysfunction (ED). The decision follows responses from representatives of the U.S. Food and Drug Administration (FDA), which raised serious concerns about the acceptable benefit/risk ratio to support the progression of the proposed program into Phase 3 studies for ED.

After reviewing the data generated in the Phase 1 and 2 studies, the FDA questioned the overall efficacy results and the clinical benefit of this product in both the general and diabetic ED populations, and cited blood pressure increases as its greatest safety concern. Though not supportive of the proposed Phase 3 studies for ED with bremelanotide, the FDA stated that it was amenable to proposals for a different drug development pathway, such as for a second-line therapy in non-responders to currently approved PDE-5 inhibitors.

"The safety of patients in our clinical program has always been our number one priority and we will work closely with the FDA, King, and our advisors to determine the next steps for the program," stated Carl Spana, Ph.D., President and Chief Executive Officer of Palatin.

Palatin and King plan to review the FDA comments in the overall context of the program in order to determine next steps related to the further development of bremelanotide for the treatment of ED.

About ED

ED is defined as the consistent inability to attain and maintain an erection sufficient for sexual intercourse. The condition is correlated with increasing age, cardiovascular disease, hypertension, diabetes, hyperlipidemia, and smoking. In addition, certain prescription drugs and psychogenic issues may contribute to ED. It is estimated that some degree of ED affects one half of all men over the age of 40 and that 150 million men worldwide suffer from ED.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's internal research and development capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling product development. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. To date, Palatin has entered into collaborations with AstraZeneca, King Pharmaceuticals, and Tyco Healthcare Mallinckrodt. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.


'/>"/>
SOURCE Palatin Technologies, Inc.; King Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... ... August 07, 2018 , ... ... A. Stark to assume the role of Sanarus Technologies President, effective immediately. Mr. Stark ... strategic development, marketing and sales experience in medical device toward finding new and innovative ...
(Date:8/2/2018)... ... August 02, 2018 , ... The American Heart ... awards on Wednesday, July 11, 2018, recognizing the hospital’s commitment to compliance with ... , , Get With The Guidelines®-Stroke Gold Plus Quality ...
(Date:8/2/2018)... , ... August 02, 2018 , ... Clay and Associates ... August 1st. Dr. Wallingford will join Dr. John Clay and Dr. Shaun O’Neill ... and a positive experience for all of their patients' dental hygiene, encapsulates the core ...
Breaking Medicine Technology:
(Date:8/11/2018)... ... August 10, 2018 , ... Georgia Urology, the largest ... Atlanta. Drs. Brent Sharpe and Froylan Gonzalez recently widened that scope by debuting ... On June 27, the physicians combined their expertise to perform a nephrectomy and ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... LegitScript certification. LegitScript is a new verification process that substance abuse providers must ... LegitScript certified means we can reach more people to help.” , Helping ...
(Date:8/7/2018)... , ... August 07, 2018 , ... Josh Sprague, Founder ... of a video preview for the upcoming Leadville 100 MTB. , Accompanied by ... miles of what he has called “one of the most iconic mountain bike race ...
(Date:8/3/2018)... ... August 03, 2018 , ... Firstaid4sport have ... Newlove first started the Firstaid4sport business in the 1990's and his son in ... of the leading providers in the UK of sports medicine products, supplying professional ...
(Date:8/2/2018)... ... ... Dr. Srini Pillay , best-selling author of TINKER DABBLE DOODLE ... less, demonstrating a “whatever” attitude toward life, people, and situations around them. , “Focus ... reason relates to being overworked. Called self-regulation depletion (SRD), this condition occurs when people ...
Breaking Medicine News(10 mins):